163 related articles for article (PubMed ID: 31580916)
1. Dipyridamole as a new drug to prevent Epstein-Barr virus reactivation.
Thomé MP; Borde C; Larsen AK; Henriques JAP; Lenz G; Escargueil AE; Maréchal V
Antiviral Res; 2019 Dec; 172():104615. PubMed ID: 31580916
[TBL] [Abstract][Full Text] [Related]
2. A Mechanism-Based Targeted Screen To Identify Epstein-Barr Virus-Directed Antiviral Agents.
Li X; Akinyemi IA; You JK; Rezaei MA; Li C; McIntosh MT; Del Poeta M; Bhaduri-McIntosh S
J Virol; 2020 Oct; 94(21):. PubMed ID: 32796077
[TBL] [Abstract][Full Text] [Related]
3. Leflunomide/teriflunomide inhibit Epstein-Barr virus (EBV)- induced lymphoproliferative disease and lytic viral replication.
Bilger A; Plowshay J; Ma S; Nawandar D; Barlow EA; Romero-Masters JC; Bristol JA; Li Z; Tsai MH; Delecluse HJ; Kenney SC
Oncotarget; 2017 Jul; 8(27):44266-44280. PubMed ID: 28574826
[TBL] [Abstract][Full Text] [Related]
4. Valpromide Inhibits Lytic Cycle Reactivation of Epstein-Barr Virus.
Gorres KL; Daigle D; Mohanram S; McInerney GE; Lyons DE; Miller G
mBio; 2016 Mar; 7(2):e00113. PubMed ID: 26933051
[TBL] [Abstract][Full Text] [Related]
5. Prazoles Targeting Tsg101 Inhibit Release of Epstein-Barr Virus following Reactivation from Latency.
Mannemuddhu SS; Xu H; Bleck CKE; Tjandra N; Carter C; Bhaduri-McIntosh S
J Virol; 2021 Jun; 95(13):e0246620. PubMed ID: 33853959
[TBL] [Abstract][Full Text] [Related]
6. A new compound, phomaherbarine A, induces cytolytic reactivation in epstein-barr virus-positive B cell lines.
Bae SE; Choi JW; Hong JW; Ku H; Sim KY; Ko GH; Jang DS; Shim SH; Park SG
Antiviral Res; 2024 Jul; 227():105906. PubMed ID: 38735576
[TBL] [Abstract][Full Text] [Related]
7. Epstein-Barr virus (EBV) reactivation and therapeutic inhibitors.
Kerr JR
J Clin Pathol; 2019 Oct; 72(10):651-658. PubMed ID: 31315893
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of Epstein-Barr Virus Lytic Reactivation by the Atypical Antipsychotic Drug Clozapine.
Anderson AG; Gaffy CB; Weseli JR; Gorres KL
Viruses; 2019 May; 11(5):. PubMed ID: 31108875
[TBL] [Abstract][Full Text] [Related]
9. Tenofovir prodrugs potently inhibit Epstein-Barr virus lytic DNA replication by targeting the viral DNA polymerase.
Drosu NC; Edelman ER; Housman DE
Proc Natl Acad Sci U S A; 2020 Jun; 117(22):12368-12374. PubMed ID: 32409608
[TBL] [Abstract][Full Text] [Related]
10. Luteolin inhibits Epstein-Barr virus lytic reactivation by repressing the promoter activities of immediate-early genes.
Wu CC; Fang CY; Hsu HY; Chen YJ; Chou SP; Huang SY; Cheng YJ; Lin SF; Chang Y; Tsai CH; Chen JY
Antiviral Res; 2016 Aug; 132():99-110. PubMed ID: 27185626
[TBL] [Abstract][Full Text] [Related]
11. Rapamycin enhances lytic replication of Epstein-Barr virus in gastric carcinoma cells by increasing the transcriptional activities of immediate-early lytic promoters.
Wang M; Wu W; Zhang Y; Yao G; Gu B
Virus Res; 2018 Jan; 244():173-180. PubMed ID: 29169830
[TBL] [Abstract][Full Text] [Related]
12. Cellular differentiation regulator BLIMP1 induces Epstein-Barr virus lytic reactivation in epithelial and B cells by activating transcription from both the R and Z promoters.
Reusch JA; Nawandar DM; Wright KL; Kenney SC; Mertz JE
J Virol; 2015 Feb; 89(3):1731-43. PubMed ID: 25410866
[TBL] [Abstract][Full Text] [Related]
13. Effects of targeting sumoylation processes during latent and induced Epstein-Barr virus infections using the small molecule inhibitor ML-792.
Garcia P; Harrod A; Jha S; Jenkins J; Barnhill A; Lee H; Thompson M; Williams JP; Barefield J; Mckinnon A; Suarez P; Shah A; Lowrey AJ; Bentz GL
Antiviral Res; 2021 Apr; 188():105038. PubMed ID: 33577806
[TBL] [Abstract][Full Text] [Related]
14. Lytic induction therapy for Epstein-Barr virus-positive B-cell lymphomas.
Feng WH; Hong G; Delecluse HJ; Kenney SC
J Virol; 2004 Feb; 78(4):1893-902. PubMed ID: 14747554
[TBL] [Abstract][Full Text] [Related]
15. Identification of a new class of small molecules that efficiently reactivate latent Epstein-Barr Virus.
Tikhmyanova N; Schultz DC; Lee T; Salvino JM; Lieberman PM
ACS Chem Biol; 2014 Mar; 9(3):785-95. PubMed ID: 24028149
[TBL] [Abstract][Full Text] [Related]
16. Interferon-γ-inducible protein 16 (IFI16) is required for the maintenance of Epstein-Barr virus latency.
Pisano G; Roy A; Ahmed Ansari M; Kumar B; Chikoti L; Chandran B
Virol J; 2017 Nov; 14(1):221. PubMed ID: 29132393
[TBL] [Abstract][Full Text] [Related]
17. Pharmacologic Activation of Lytic Epstein-Barr Virus Gene Expression without Virion Production.
Lee J; Kosowicz JG; Hayward SD; Desai P; Stone J; Lee JM; Liu JO; Ambinder RF
J Virol; 2019 Oct; 93(20):. PubMed ID: 31341058
[TBL] [Abstract][Full Text] [Related]
18. Valganciclovir suppressed Epstein Barr virus reactivation during immunosuppression with alemtuzumab.
Gill H; Hwang YY; Chan TS; Pang AW; Leung AY; Tse E; Kwong YL
J Clin Virol; 2014 Apr; 59(4):255-8. PubMed ID: 24507802
[TBL] [Abstract][Full Text] [Related]
19. Sildenafil prevents HDACi-induced Epstein-Barr virus reactivation through the PKG pathway in NK/T cell lymphoma; potential implications for HDACi-mediated fatal complications.
Kim JH; Kim WS; Park C
Antiviral Res; 2021 May; 189():105063. PubMed ID: 33741394
[TBL] [Abstract][Full Text] [Related]
20. Stress-Induced Epstein-Barr Virus Reactivation.
Sausen DG; Bhutta MS; Gallo ES; Dahari H; Borenstein R
Biomolecules; 2021 Sep; 11(9):. PubMed ID: 34572593
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]